Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee; Amendment of Notice, 12968 [2017-04529]

Download as PDF 12968 Federal Register / Vol. 82, No. 44 / Wednesday, March 8, 2017 / Notices As a general matter, information collections will not result in any new system of records containing privacy information and will not ask questions of a sensitive nature, such as sexual behavior and attitudes, religious beliefs, and other matters that are commonly considered private. Households, Businesses, Organizations, and/or State, Local or Tribal Government. There is no cost to respondents other than their time. The estimated annualized burden hours for this data collection activity are 9,690. This is a revision to the previously approved collection to reduce the burden hours from 12,400 to 9,690 hours as a result of the previous usage and anticipated future usage of this Generic Information Collection. Respondents will be screened and selected from Individuals and ESTIMATED ANNUALIZED BURDEN HOURS Number of respondents Type of collection Annual frequency per response Hours per response Total hours Online surveys ................................................................................................. Discussion Groups ........................................................................................... Focus groups ................................................................................................... Web site/app usability testing .......................................................................... Interviews ......................................................................................................... 10,500 280 640 2,000 800 1 1 1 1 1 30/60 2 2 30/60 2 5,250 560 1280 1,000 1,600 Totals ........................................................................................................ 14,220 ........................ ........................ 9,690 Leroy A. Richardson, Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention. Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area). Please call the Information Line for up-to-date information on this meeting. [FR Doc. 2017–04510 Filed 3–7–17; 8:45 am] In the Federal Register of January 11, 2017 (82 FR 3333), FDA announced that the joint meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee would be held on March 13–14, 2017. On page 3334, in the first column, under the ADDRESSES caption, the address of the meeting and the phone number in the first six lines is changed to read as follows: SUPPLEMENTARY INFORMATION: BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2017–N–0067] Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee; Amendment of Notice AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) is announcing an amendment to the notice of the joint meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee. This meeting was announced in the Federal Register of January 11, 2017. The amendment is being made to reflect a change in the ADDRESSES portion of the document. There are no other changes. FOR FURTHER INFORMATION CONTACT: Stephanie L. Begansky, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993–0002, 301– 796–9001, FAX: 301–847–8533, email: AADPAC@fda.hhs.gov, or FDA mstockstill on DSK3G9T082PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:34 Mar 07, 2017 Jkt 241001 The meeting will be held at the Tommy Douglas Conference Center, 10000 New Hampshire Ave., Silver Spring, MD 20903. The conference center’s telephone number is 240–645– 4000. This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees. ADDRESSES: Dated: March 3, 2017. Janice M. Soreth, Associate Commissioner for Special Medical Programs. [FR Doc. 2017–04529 Filed 3–7–17; 8:45 am] BILLING CODE 4164–01–P PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES Indian Health Service Notice To Propose the Re-Designation of the Service Delivery Area for the Passamaquoddy Tribe at Indian Township Indian Health Service, HHS. Notice. AGENCY: ACTION: This notice advises the public that the Indian Health Service (IHS) proposes to expand the geographic boundaries of the Purchased/Referred Care (PRC) Service Delivery Area (SDA) for the Passamaquoddy Tribe’s reservation at Indian Township (Passamaquoddy at Indian Township or Tribe) in Maine. This notice does not propose to change or expand the PRC SDA for the Tribe’s Pleasant Point reservation. This notice only relates to the expansion of the Tribe’s PRC SDA for the Indian Township reservation. DATES: Comments must be submitted April 7, 2017. ADDRESSES: You may submit comments in one of four ways detailed below. However, we cannot accept comments by facsimile (FAX) transmission due to staff and resource limitations. Please choose one method below: 1. Electronically. You may submit electronic comments on this regulation to http://www.regulations.gov. Follow the ‘‘Submit a Comment’’ instructions. 2. By regular mail. You may mail written comments to the following address ONLY: Betty Gould, Regulations Officer, Indian Health Service, 5600 Fishers Lane, Mailstop: 09E70, Rockville, Maryland 20852. Please allow sufficient time for mailed comments to SUMMARY: E:\FR\FM\08MRN1.SGM 08MRN1

Agencies

[Federal Register Volume 82, Number 44 (Wednesday, March 8, 2017)]
[Notices]
[Page 12968]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-04529]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-N-0067]


Joint Meeting of the Drug Safety and Risk Management Advisory 
Committee and the Anesthetic and Analgesic Drug Products Advisory 
Committee; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing an 
amendment to the notice of the joint meeting of the Drug Safety and 
Risk Management Advisory Committee and the Anesthetic and Analgesic 
Drug Products Advisory Committee. This meeting was announced in the 
Federal Register of January 11, 2017. The amendment is being made to 
reflect a change in the ADDRESSES portion of the document. There are no 
other changes.

FOR FURTHER INFORMATION CONTACT: Stephanie L. Begansky, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-
796-9001, FAX: 301-847-8533, email: AADPAC@fda.hhs.gov, or FDA Advisory 
Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
Washington, DC area). Please call the Information Line for up-to-date 
information on this meeting.

SUPPLEMENTARY INFORMATION: In the Federal Register of January 11, 2017 
(82 FR 3333), FDA announced that the joint meeting of the Drug Safety 
and Risk Management Advisory Committee and the Anesthetic and Analgesic 
Drug Products Advisory Committee would be held on March 13-14, 2017. On 
page 3334, in the first column, under the ADDRESSES caption, the 
address of the meeting and the phone number in the first six lines is 
changed to read as follows:

ADDRESSES: The meeting will be held at the Tommy Douglas Conference 
Center, 10000 New Hampshire Ave., Silver Spring, MD 20903. The 
conference center's telephone number is 240-645-4000.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.

    Dated: March 3, 2017.
Janice M. Soreth,
Associate Commissioner for Special Medical Programs.
[FR Doc. 2017-04529 Filed 3-7-17; 8:45 am]
 BILLING CODE 4164-01-P